ResearchMoz.us

ResearchMoz is the one stop online destination to find and buy market research reports and Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.

Wednesday, 2 September 2015

Recurrent Malignant Glioma - Pipeline Review, H2 2015 : Global Industry Growth, Research, Analysis, Shares and Forecast

Posted on 01:03 by Unknown
Product Synopsis

Recurrent Malignant Glioma - Pipeline Review, H2 2015

Summary

Global Markets Directs, Recurrent Malignant Glioma - Pipeline Review, H2 2015, provides an overview of the Recurrent Malignant Gliomas therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Recurrent Malignant Glioma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Recurrent Malignant Glioma and special features on late-stage and discontinued projects.


Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Recurrent Malignant Glioma
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Recurrent Malignant Glioma and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Recurrent Malignant Glioma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Recurrent Malignant Glioma pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products


Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Recurrent Malignant Glioma
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Recurrent Malignant Glioma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

For More Information Kindly Contact:

ResearchMoz
Mr. Nachiket Ghumare, +1–518–621–2074
USA-Canada Toll Free: 866–997–4948

Posted in , , , | No comments

Elephantiasis (Lymphatic Filariasis) - Pipeline Review, H2 2015 : Global Industry Growth, Research, Analysis, Shares and Forecast

Posted on 00:59 by Unknown
Product Synopsis

Elephantiasis (Lymphatic Filariasis) - Pipeline Review, H2 2015

Summary

Global Markets Directs, Elephantiasis (Lymphatic Filariasis) - Pipeline Review, H2 2015, provides an overview of the Elephantiasis (Lymphatic Filariasis)s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Elephantiasis (Lymphatic Filariasis), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Elephantiasis (Lymphatic Filariasis) and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.


The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Elephantiasis (Lymphatic Filariasis)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Elephantiasis (Lymphatic Filariasis) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Elephantiasis (Lymphatic Filariasis) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Elephantiasis (Lymphatic Filariasis) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products


Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Elephantiasis (Lymphatic Filariasis)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Elephantiasis (Lymphatic Filariasis) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

For More Information Kindly Contact:

ResearchMoz
Mr. Nachiket Ghumare, +1–518–621–2074
USA-Canada Toll Free: 866–997–4948

Posted in , , , | No comments

Otitis Media - Pipeline Review, H2 2015 : Global Industry Growth, Research, Analysis, Shares and Forecast

Posted on 00:45 by Unknown
Summary

Global Markets Directs, Otitis Media - Pipeline Review, H2 2015, provides an overview of the Otitis Medias therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Otitis Media, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Otitis Media and special features on late-stage and discontinued projects.


Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


Scope

- The report provides a snapshot of the global therapeutic landscape of Otitis Media
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Otitis Media and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Otitis Media products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Otitis Media pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Otitis Media

Read All Pharmaceutical Market Research Reports @ http://www.researchmoz.us/pharmaceutical-market-reports-38.html

- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Otitis Media pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

For More Information Kindly Contact:

ResearchMoz
Mr. Nachiket Ghumare, +1–518–621–2074
USA-Canada Toll Free: 866–997–4948

Posted in , , | No comments

Acute Heart Failure - Pipeline Review, H2 2015 : Global Industry Growth, Research, Analysis, Shares and Forecast

Posted on 00:40 by Unknown
Product Synopsis

Acute Heart Failure - Pipeline Review, H2 2015

Summary

Global Markets Directs, Acute Heart Failure - Pipeline Review, H2 2015, provides an overview of the Acute Heart Failures therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Acute Heart Failure, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Heart Failure and special features on late-stage and discontinued projects.


Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Acute Heart Failure
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Acute Heart Failure and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Acute Heart Failure products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Acute Heart Failure pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products


Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Acute Heart Failure
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Acute Heart Failure pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

For More Information Kindly Contact:

ResearchMoz
Mr. Nachiket Ghumare, +1–518–621–2074
USA-Canada Toll Free: 866–997–4948

Posted in , , | No comments

Vaccinex, Inc. - Product Pipeline Review - 2015: Global Industry Growth, Research, Analysis, Shares and Forecast

Posted on 00:37 by Unknown
Product Synopsis

Vaccinex, Inc. - Product Pipeline Review - 2015

Summary

Global Markets Directs, Vaccinex, Inc. - Product Pipeline Review - 2015, provides an overview of the Vaccinex, Inc.s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Vaccinex, Inc.s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.


Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Vaccinex, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Vaccinex, Inc.s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the products developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Vaccinex, Inc.s pipeline products


Reasons to buy

- Evaluate Vaccinex, Inc.s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Vaccinex, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Vaccinex, Inc.s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Vaccinex, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Vaccinex, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Vaccinex, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

For More Information Kindly Contact:

ResearchMoz
Mr. Nachiket Ghumare, +1–518–621–2074
USA-Canada Toll Free: 866–997–4948

Posted in , , , , | No comments

ImmunoBiology Limited - Product Pipeline Review - 2015: Global Industry Growth, Research, Analysis, Shares and Forecast

Posted on 00:19 by Unknown
Product Synopsis

ImmunoBiology Limited - Product Pipeline Review - 2015

Summary

Global Markets Directs, ImmunoBiology Limited - Product Pipeline Review - 2015, provides an overview of the ImmunoBiology Limiteds pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of ImmunoBiology Limiteds, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.


Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of ImmunoBiology Limited including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of ImmunoBiology Limiteds human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the products developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the ImmunoBiology Limiteds pipeline products


Reasons to buy

- Evaluate ImmunoBiology Limiteds strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of ImmunoBiology Limited in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the ImmunoBiology Limiteds R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of ImmunoBiology Limited and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of ImmunoBiology Limited
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of ImmunoBiology Limited and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

For More Information Kindly Contact:

ResearchMoz
Mr. Nachiket Ghumare, +1–518–621–2074
USA-Canada Toll Free: 866–997–4948

Posted in , , | No comments

Bionor Pharma ASA - Product Pipeline Review - 2015 | Researchmoz

Posted on 00:14 by Unknown
Product Synopsis

Bionor Pharma ASA - Product Pipeline Review - 2015

Summary

Global Markets Directs, Bionor Pharma ASA - Product Pipeline Review - 2015, provides an overview of the Bionor Pharma ASAs pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Bionor Pharma ASAs, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.


Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Bionor Pharma ASA including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Bionor Pharma ASAs human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the products developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Bionor Pharma ASAs pipeline products


Reasons to buy

- Evaluate Bionor Pharma ASAs strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Bionor Pharma ASA in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Bionor Pharma ASAs R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Bionor Pharma ASA and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Bionor Pharma ASA
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Bionor Pharma ASA and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

For More Information Kindly Contact:

ResearchMoz
Mr. Nachiket Ghumare, +1–518–621–2074
USA-Canada Toll Free: 866–997–4948

Posted in , | No comments

Marina Biotech, Inc. - Product Pipeline Review - 2015: Global Industry Growth, Research, Analysis, Shares and Forecast

Posted on 00:07 by Unknown
Product Synopsis

Marina Biotech, Inc. - Product Pipeline Review - 2015

Summary

Global Markets Directs, Marina Biotech, Inc. - Product Pipeline Review - 2015, provides an overview of the Marina Biotech, Inc.s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Marina Biotech, Inc.s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.


Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Marina Biotech, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Marina Biotech, Inc.s human therapeutic division and enlists all their major and minor projects



- The report features product description and descriptive mechanism of action for key pipeline products along with the products developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Marina Biotech, Inc.s pipeline products

Reasons to buy

- Evaluate Marina Biotech, Inc.s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Marina Biotech, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Marina Biotech, Inc.s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Marina Biotech, Inc. and exploit collaboration and partnership opportunities


For Market Research Latest Reports Visit @ http://www.researchmoz.us/latest-report.html

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Marina Biotech, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Marina Biotech, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

For More Information Kindly Contact:
ResearchMoz
Mr. Nachiket Ghumare, +1–518–621–2074
USA-Canada Toll Free: 866–997–4948

Posted in , , , | No comments

Merus B.V. - Product Pipeline Review - 2015

Posted on 00:02 by Unknown
Product Synopsis

Merus B.V. - Product Pipeline Review - 2015

Summary

Global Markets Directs, Merus B.V. - Product Pipeline Review - 2015, provides an overview of the Merus B.V.s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Merus B.V.s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.


Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Merus B.V. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Merus B.V.s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the products developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Merus B.V.s pipeline products


Reasons to buy

- Evaluate Merus B.V.s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Merus B.V. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Merus B.V.s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Merus B.V. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Merus B.V.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Merus B.V. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

For More Information Kindly Contact:
ResearchMoz
Mr. Nachiket Ghumare, +1–518–621–2074
USA-Canada Toll Free: 866–997–4948

Posted in , | No comments

Tuesday, 1 September 2015

Healthcare IT Industry : United States Healthcare Information Technology Software Industry 2015

Posted on 23:54 by Unknown
Product Synopsis

The United States Healthcare Information Technology Software Industry Report 2015 is a professional and in-depth study on the current state of the Healthcare Information Technology Software industry.

The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The Healthcare Information Technology Software market analysis is provided for the United States markets including development trends, competitive landscape analysis, and key regions development status.

Development policies and plans are discussed as well as manufacturing processes and Bill of Materials cost structures are also analyzed. This report also states import/export consumption, supply and demand Figures, cost, price, revenue and gross margins.


The report focuses on United States major leading industry players providing information such as company profiles, product picture and specification, capacity, production, price, cost, revenue and contact information. Upstream raw materials and equipment and downstream demand analysis is also carried out. The Healthcare Information Technology Software industry development trends and marketing channels are analyzed. Finally the feasibility of new investment projects are assessed and overall research conclusions offered.

With 166 tables and figures the report provides key statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market.

Table Of Content

Chapter One Industry Overview
1.1 Definition and Specifications of Healthcare Information Technology Software
1.2 Classification of Healthcare Information Technology Software
1.3 Applications of Healthcare Information Technology Software
1.4 Industry Chain Structure of Healthcare Information Technology Software
1.5 Industry Overview of Healthcare Information Technology Software
1.6 Industry Policy Analysis of Healthcare Information Technology Software
1.7 Industry News Analysis of Healthcare Information Technology Software

Chapter Two Manufacturing Cost Structure Analysis of Healthcare Information Technology Software
2.1 Bill of Materials (BOM) of Healthcare Information Technology Software
2.2 BOM Price Analysis of Healthcare Information Technology Software
2.3 Labor Cost Analysis of Healthcare Information Technology Software
2.4 Depreciation Cost Analysis of Healthcare Information Technology Software
2.5 Manufacturing Cost Structure Analysis of Healthcare Information Technology Software
2.6 Manufacturing Process Analysis of Healthcare Information Technology Software



Chapter Three Technical Data and Manufacturing Plants Analysis

3.1 Capacity and Commercial Production Date of United States Key Manufacturers in 2014
3.2 Manufacturing Plants Distribution of United States Key Healthcare Information Technology Software Manufacturers in 2014
3.3 R&D Status and Technology Source of United States Healthcare Information Technology Software Key Manufacturers in 2014
3.4 Raw Materials Sources Analysis of United States Healthcare Information Technology Software Key Manufacturers in 2014

Chapter Four Sales Analysis of Healthcare Information Technology Software by Regions, Product Type, and Applications
4.1 United States Sales of Healthcare Information Technology Software by Regions 2010-2015
4.2 United States Sales of Healthcare Information Technology Software by Product Type 2010-2015
4.3 United States Sales of Healthcare Information Technology Software by Applications 2010-2015
4.4 Price Analysis of United States Healthcare Information Technology Software Key Manufacturers in 2015
4.5 United States Capacity, Production, Import, Export, Sales, Price, Cost and Revenue of Healthcare Information Technology Software 2010-2015

Chapter Five Sales Revenue Analysis of Healthcare Information Technology Software by Regions, Product Type, and Applications
5.1 United States Sales Revenue of Healthcare Information Technology Software by Regions 2010-2015
5.2 United States Sales Revenue of Healthcare Information Technology Software by Product Type 2010-2015
5.3 United States Sales Revenue of Healthcare Information Technology Software by Applications 2010-2015
5.4 Sales Price Analysis of Healthcare Information Technology Software by Regions, Product Type, and Applications 2010-2015

Chapter Six Analysis of Healthcare Information Technology Software Production, Supply, Sales and Demand Market Status 2010-2015
6.1 Capacity Production Sales Revenue of Healthcare Information Technology Software 2010-2015
6.2 Production Sales Market Share Analysis of Healthcare Information Technology Software 2014-2015
6.3 Import, Export and United States Local Sales of Healthcare Information Technology Software 2010-2015
6.4 Supply (Production), Local Sales and Relationship between Supply and Demand of Healthcare Information Technology Software 2010-2015
6.5 Price, Cost, Gross Margin of Healthcare Information Technology Software 2010-2015

For More Information Kindly Contact:
ResearchMoz
Mr. Nachiket Ghumare, +1–518–621–2074
USA-Canada Toll Free: 866–997–4948

Posted in , | No comments
Subscribe to: Posts (Atom)